Telix Pharmaceuticals: The Radiopharma Operating System Is The Real Moat
Telix is evolving into a vertically integrated radiopharmaceutical platform, leveraging diagnostics, therapeutics, isotope generation, and distribution for a durable competitive edge. TLX's Illuccix and Gozellix franchises generate commercial scale, funding a late-stage oncology pipeline and supporting double-digit precision medicine growth. Management expects 2026 revenue to exceed $1 billion, with robust product demand, expanding infrastructure, and a diversified pivotal-stage therapeutic portfolio across prostate, kidney, and brain cancers.
Does Telix Pharmaceuticals Limited (TLX) Have the Potential to Rally 86.17% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 86.2% in Telix Pharmaceuticals Limited (TLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Telix Pharmaceuticals Limited (TLX) Discusses Neurologic Oncology Portfolio and Advances in Therapeutic and Diagnostic Agents Transcript
Telix Pharmaceuticals Limited (TLX) Discusses Neurologic Oncology Portfolio and Advances in Therapeutic and Diagnostic Agents Transcript
Telix Pharmaceuticals: PSMA Radiopharmaceutical Player Is Revving Up
Telix Pharmaceuticals Limited offers a potent mix of derisking, downside cushion, and accelerating clinical/commercial momentum in the radiopharmaceutical and diagnostic space. TLX reported Q1 revenue of $230M (up 11% QoQ), reaffirmed FY26 guidance of $950M–$970M, and expects further upside from new diagnostic approvals. Strategic collaborations (notably with Regeneron) and high-profile board appointments reinforce TLX's growth trajectory and potential acquisition appeal.
Telix Pharmaceuticals Limited (TLX) Discusses Advances in PSMA Therapy and Insights from the OPTIMAL-PSMA Trial with TLX597 Transcript
Telix Pharmaceuticals Limited (TLX) Discusses Advances in PSMA Therapy and Insights from the OPTIMAL-PSMA Trial with TLX597 Transcript
All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy
Telix Pharmaceuticals Limited (TLX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Telix Shares May Gain on the Distribution Deal With Cardinal Health
TLX rolls out a new e-commerce platform connecting users to top retail pharmacies, aiming to boost savings, improve access, and expand its digital health services.
Telix Pharmaceuticals Gets FDA Approval for Prostate Cancer Screening Agent
Shares of Australia-based Telix Pharmaceuticals (TLX) rose 6% Friday as the U.S. Food and Drug Administration (FDA) approved the biopharma firm's agent for use in tests to screen for prostate cancer.
Telix Pharmaceuticals Limited (TLX) Upgraded to Buy: What Does It Mean for the Stock?
Telix Pharmaceuticals Limited (TLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes Telix Pharmaceuticals Limited (TLX) a Good Fit for 'Trend Investing'
Telix Pharmaceuticals Limited (TLX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
